Skip to content

The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea (OSA): Comfort & Performance Trial

The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea (OSA): Comfort & Performance Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03075722
Enrollment
14
Registered
2017-03-09
Start date
2017-03-09
Completion date
2017-04-15
Last updated
2017-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea, Sleep Disordered Breathing

Brief summary

This investigation is designed to evaluate the performance (treatment and leak), comfort (subjective feedback), stability (subjective feedback, leak) as well as the participant's overall acceptance of the Saturn mask amongst OSA participants. An important factor in this investigation will be the testing of our two different seal sizes on the participants (small and medium size). A total number of 15 participants who currently use nasal or nasal pillow masks will be recruited for the trial. A subset of participants have been selected based on their anthropometric measurements collected in previous trials using nasal and nasal pillow masks at this site (CIA-103). Participants from previous NZ trials may be recruited into this trial with their consent. All the participants will be recruited by WellSleep, Wellington. Participants will use the trial mask in home for a period of 7 ± 3 days. Baseline data will be collected from the participant during the first visit, the prior 7 days of CPAP usage data will be downloaded and stored for our analysis. The participant will use the trial device on their usual CPAP/APAP setting and device for the duration of the trial. This study will be conducted in accordance with ICH/GCP guidelines. No deviation from the protocol will be implemented without prior review and approval of the sponsor except where it may be necessary to eliminate an immediate hazard to a research participant. In such case, the deviation will be reported to the sponsor as soon as possible.

Interventions

DEVICESaturn nasal mask

Nasal mask for the treatment of obstructive sleep apnea (OSA)

Sponsors

Fisher and Paykel Healthcare
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult (18+ years of age) * Able to give consent * AHI ≥ 5 on diagnostic night * Prescribed a CPAP device after successful OSA diagnosis * Existing nasal or nasal pillow mask user

Exclusion criteria

* Inability to give consent * Participants who are in a coma or a decreased level of consciousness. * Anatomical or physiological conditions making APAP therapy inappropriate (e.g. unconsolidated facial structure) * Commercial drivers who are investigated by New Zealand Transport Agency (NZTA) * Current diagnosis of CO2 retention * Pregnant or may think they are pregnant.

Design outcomes

Primary

MeasureTime frameDescription
NoiseUp to 7 ± 3 days in-homeSubjective questionnaire
DraftUp to 7 ± 3 days in-homeSubjective questionnaire
Treatment efficacyUp to 7 ± 3 days in-homeObtained from participant's CPAP device
ComfortUp to 7 ± 3 days in-homeSubjective questionnaire
StabilityUp to 7 ± 3 days in-homeSubjective questionnaire
Objective leak dataUp to 7 ± 3 days in-homeObtained from participant's CPAP device
Subjective measurement of leakUp to 7 ± 3 days in-homeSubjective questionnaire

Secondary

MeasureTime frameDescription
UsabilityUp to 7 ± 3 days in-homeSubjective questionnaire
Preference of maskUp to 7 ± 3 days in-homeSubjective questionnaire

Countries

New Zealand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026